| Name | Title | Contact Details |
|---|
SIGA Technologies is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
454 Life Sciences' system enables one individual to prepare and sequence an entire genome after performing a single sample preparation, irrespective of the size of the genome being studied. The hallmark of 454 Life Sciences' technology is the
Interleuken Genetics is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pacific Biosciences is developing an environment in which scientists can seamlessly integrate multiple data types from multiple sources and deploy advanced bioinformatics methods to elucidate the complexity of living systems. Therefore, we are committed
Pinetree Therapeutics is an award-winning, pre-clinical stage biotechnology company based in Cambridge, Massachusetts. We are dedicated to finding solutions for unmet medical need, such as drug resistance and tumor recurrence, in targeted therapy by degradation of disease-causing proteins with AbReptorTM platform. Novel degrader drugs have been exciting scientific field, due to its distinct mechanism of action (removal of disease-causing protein). AbReptorTM was developed for targeted degradation on membrane bound and extracellular proteins causing diseases. Receptor tyrosine kinase (RTK) and non-RTK inhibitors have made huge progress in the past few years, but their application is limited due to specificity, drug resistance, and on-target toxicity. Our platform`s RTK degraders promise to redefine their distinctive mutation-agnostic properties, differing from existing RTK therapeutics field. With the pre-clinical animal study, our lead molecule demonstrated on-target degradation, mutation agnostic anti-tumor effect, and potent anti-tumor effect in RTK inhibitor resistant tumor. Surprisingly, no signs of toxicity were found in rodent and cynomolgus monkey. Furthermore, it would unluck full potential to solve limitation of RTK and non-RTK therapeutics. Immune checkpoint inhibitors (ICIs) field made an initial breakthrough with poor response rate, high toxicity profiles, and exhausted poor clinical outcome. Our platform has full potential to solve the current problem of immune checkpoint inhibitors (ICIs), PD-(L)1 inhibitors. Our PD-(L)1 degrader is the first ever in-class to demonstrate enhanced anti-tumor immunity in pre-clinical animal studies. Pinetree Therapeutics` lead molecule is in pre-clinical IND stage, and we are committed to expanding our platforms to other target proteins, such as RTKs, non-RTKs, and ICIs. We believe our platform has the potential to transform the field of medicine and revolutionize the treatment of cancer and other diseases.